ACADIA Pharmaceuticals Inc. (ACAD) stock trades up, “Buy” rating reiterated by Ladenburg Thalmann Financial Services Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares rose on Thursday February 2 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.10% fell 34 points, or 0.2%, to 19,858. The S&P 500 SPX, -0.11% lost 4 points to 2,276, a drop of 0.2%. The Nasdaq Composite Index COMP, -0.05% slid 16 points, or 0.3%, to 5,626. Among the most actively traded Nasdaq stocks was Facebook Inc FB, +0.31% which fell 0.7% a day after it reported its quarterly results.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its Buy rating reiterated by equities researchers at Ladenburg Thalmann Financial Services in a research note to investors. Ladenburg Thalmann Financial Services currently has a rating of Buy on the stock. The one-year price target of $41.73 is above the opening price of $34.57, causing a number of other analysts to comment on the company in recent days. Looking back over the last year, ACADIA Pharmaceuticals Inc. stock has a high of $42.49. Usually, after analysts give a “reiterated rating” report on a stock, they will later issue periodic revisions, usually followed by a price target change.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) opened at $34.57 yesterday and traded in a range between, $34.16 and $34.80, and last traded at $34.67, which is an increase of $0.18 from the previous closing price.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) currently has a market cap of 4.20B.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Average Daily Trading Volume

The stock’s average daily volume is 2,512,820 shares out of a total float 94,892,000 and some 148,065 shares crossed the trading desk yesterday, 96 percent below the average. lower than normal. Look for trading volume to pick up in the coming days as momentum traders often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have teams of analysts that research thousands of stocks, so it is good confirmation to see them buying a stock you are researching.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By identifying trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.

With that in mind, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) now has a 50-day MA of $30.19 and 200-day MA of $30.19. It has traded in a 52-week range between $16.64 – 42.49 and today’s last price is 18.40%% lower than the 52 week high of $42.49.

Indeed, earnings growth is among the most critical things to look at in regards to stock investing and, accordingly, investors watch for companies that have been successful at growing their earnings at least 25% or more for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Latest News

Leave a Reply